ArticleOncotarget2015
MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- The relationship of miR-155 host gene polymorphism in the susceptibility of cancer: a systematic review and meta-analysis.Frontiers in genetics · 2025Pooled it
- MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Identification of DMP1 as Novel p53 Repressed Transcriptional Target.International journal of molecular sciences · 2026Article
- Intratumor microbiota Delftialacustiris correlated with METTL3 to control development of papillary thyroid carcinoma.Cancer cell international · 2026Article
- Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression.Current issues in molecular biology · 2025Article
- A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection.Medicinal research reviews · 2025Review
- MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.Frontiers in oncology · 2025Review
- Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer.Cancer metastasis reviews · 2024Review
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets.Current drug targets · 2024Review
- Unraveling Therapeutic Opportunities and the Diagnostic Potential of microRNAs for Human Lung Cancer.Pharmaceutics · 2023Review
- SRSF5 regulates alternative splicing ofRNA biology · 2021Article
- MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.Journal of bioenergetics and biomembranes · 2021Article
- Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.International journal of molecular sciences · 2021Article
- The MicroRNA Prediction Models as Ancillary Diagnosis Biomarkers for Urothelial Carcinoma in Patients With Chronic Kidney Disease.Frontiers in medicine · 2021Article
- Mechanisms regulating DMTF1β/γ expression and their functional interplay with DMTF1α.International journal of oncology · 2021Article
- Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.Cancers · 2019Review
- MiR-155-5p modulates HSV-1 replication via the epigenetic regulation of SRSF2 gene expression.Epigenetics · 2019Article
- miR‑675 promotes colorectal cancer cell growth dependent on tumor suppressor DMTF1.Molecular medicine reports · 2019Article
- Identifying Disease-Gene Associations With Graph-Regularized Manifold Learning.Frontiers in genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-155 (miR-155) is dysregulated in human cancers. In this study, we reported that miR-155 was over-expressed in bladder cancer tissues. We found that miR-155 promoted cell proliferation in vitro and tumorigenesis in vivo. MiR-155 directly reduced the expression of the tumor suppressor DMTF1. The expression of DMTF1 was decreased in bladder cancer tissues. Similar to the restoring miR-155 expression, knockdown of DMTF1 promoted cell growth and cell cycle progression, whereas DMTF1 over-expression rescued the effect of miR-155. Moreover, we investigated DMTF1-Arf-p53 pathway and found that DMTF1 worked in both p53-dependent and p53-independent manners. Taken together, our findings suggested that miR-155 functions as a tumor promoter in bladder cancer, which is partially through repressing DMTF1 expression. The identification of miR-155 and its novel target DMTF1 will be valuable in developing diagnostic markers and therapeutic applications for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.